News
PMV cues up filing for first p53-directed cancer therapy
PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.
News
Roche taps Simcere for autoimmune trispecific for $1.53bn
Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.
R&D
Decarbonising respiratory care requires a new kind of generi...
Generics manufacturers have long played a critical role in supporting the sustainability of the NHS, delivering affordable medicines at scale, expanding patient access, and helping healthca
News
Novartis sets sights on new oral MS drug after phase 3 wins
Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
News
GSK pushes 'next-generation' mRNA flu shot into phase 3
Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
